

3739



Please type a plus sign (+) inside this box → ☐ +

PTO/SB/21 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	09/865,195
Filing Date	May 24, 2001
First Named Inventor	William L. Hunter
Group Art Unit	3739
Examiner Name	Not Yet Assigned
Attorney Docket No.	110129.420C2

RECEIVED  
APR 10 2002  
TECHNOLOGY CENTER R3700

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement; Forms PTO-1449 (6 Sheets) <input checked="" type="checkbox"/> Cited References (66) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____ _____
---	---	---

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Jeffrey C. Pepe, Ph.D.	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	05-Apr-2002	

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.		
Typed or printed name	Nathan Adderson	
Signature		Date: 4/5/02



BET  
6-20-02  
#61 IDS  
PATENT (suppl.)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : William L. Hunter et al.  
Application No. : 09/865,195  
Filed : May 24, 2001  
For : COMPOSITIONS AND METHODS FOR TREATING DISEASE  
UTILIZING A COMBINATION OF RADIOACTIVE THERAPY  
AND CELL-CYCLE INHIBITORS

Art Unit : 3739  
Docket No. : 110129.420C2  
Date : April 5, 2002

Commissioner for Patents  
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method.

Applicants note Reference AI, on page 1 of the attached Forms PTO-1449, is written in German. Accordingly, the Examiner's attention is respectfully directed to Reference AB which claims identical priority and is written in English.

Applicants note Reference AN, on page 1 of the attached Forms PTO-1449, is written in French. Accordingly, the Examiner's attention is respectfully directed to pg. 396 of the reference, which provides an English language summary.


Applicants note Reference ED, on page 5. of the attached Forms PTO-1449, is written in French. Accordingly, the Examiner's attention is respectfully directed to pg. 51 of the reference, which provides and English language summary.

Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

  
\_\_\_\_\_  
Jeffrey C. Pepe, Ph.D.  
Registration No. 46,985

JCP:nka

Enclosures:

Postcard  
Form PTO/SB/21  
Forms PTO-1449 (6 sheets)  
Cited References (66)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

D:\NrPortbl\iManage\NATHANA\272730\_1.DOC